Clinical Features and Outcome of Chronic Viral Hepatitis with Acute Exacerbation in Patients with Concurrent Infections of Hepatitis B and C Virus

Chuang, Chia-Sheng; Tung, Shui‐Yi; Lee, I.-Lin; Shen, Chien-Heng; Wei, Kuo‐Liang; Chang, Te‐Sheng; Wu, Cheng‐Shyong

doi:10.1007/s10620-007-9891-4

Cited by 6 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Samples obtained prior to ART initiation showed that triply infected patients had a trend toward lower HBV DNA levels, similar to other reports in HBV/HCV patients. [22][23][24] No difference in HCV RNA levels in the triply infected patients was observed when compared to the HIV/ HCV coinfected group; this result differs from a recent study. 24 Hepatitis D virus infection occurred more often in those with triple infection, suggesting that the intravenous/parenteral route is the most likely mode of transmission of these infections.…”

Section: Discussioncontrasting

confidence: 98%

Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis

Jain

Seremba

Bhore

et al. 2012

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Noninvasive markers of liver fibrosis, measured at baseline, have been shown to predict liver-related mortality. It remains unknown if a change in the value of the scores over time predicts mortality in patients with HIV and viral hepatitis. In this retrospective study, survival in HIV/hepatitis B virus (HBV; n = 67), HIV/hepatitis C virus (HCV; n = 43), and HIV/HBV/HCV (n = 41) patients was examined using Kaplan-Meier life table analysis. Aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and FIB-4 scores, two noninvasive markers of liver fibrosis, were calculated at baseline and at last available clinical follow-up to determine the change in fibrosis score. Factors associated with mortality were assessed by Cox proportional hazards, including the change in the noninvasive marker score between the two time points. All-cause mortality was determined by Social Security Death Index and chart review. Sixty-seven were coinfected with HIV/HBV, 43 with HIV/HCV, and 41 were triply infected (HIV/HBV/HCV). Kaplan-Meier analysis showed similar survival for the three groups at 7 years of follow-up ( p = 0.10). However, median length of follow-up was lower in HIV/HCV (60.5; range 0-102) compared to HIV/HBV (75.7; 12.3-126.5) and HIV/HBV/HCV (80.0; 2.7-123) months, respectively, p = 0.02. Baseline fibrosis score ( p = 0.002), an increase in the value for noninvasive measurements for fibrosis ( p < 0.001), and the presence of HIV/HCV coinfection ( p = 0.041) were each associated with higher risk for mortality. Baseline fibrosis score ( p = 0.03) and an increase in FIB-4 score ( p = 0.05) were independent predictors of all-cause mortality, but liver-related mortality was not evaluated. In this study, baseline fibrosis score was predictive of 7-year all-cause mortality. Further studies are needed in a prospective cohort to evaluate the predictive value of monitoring changes in fibrosis scores over time to predict mortality in patients with viral hepatitis.

show abstract

Section: Discussioncontrasting

confidence: 98%

Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis

Jain

Seremba

Bhore

et al. 2012

AIDS Patient Care and STDs

View full text Add to dashboard Cite

show abstract

“…In the setting of active i.v drug abuse [1][2][3][4][5]8], and also in regions where the prevalence of chronic hepatitis by HBV, HDV and HCV is proportionally elevated or reincreasing [1][2][3][4][5], both co-infections and superinfections may occur, sometimes leading to a rapidly evolving liver failure responsible for organ transplantation and death, or late sequelae like cirrhosis or hepatocellular carcinoma [3][4][5][7][8][9]. Concurrently, other hepatotropic viruses like HGV are emerging [10], since laboratory diagnosis benefits from an excellent, endless progress [10,11].…”

Section: Introductionmentioning

confidence: 99%

Fulminant hepatitis by concurrent acute HBV-HCV infection successfully treated with antivirals while seeking for an orthotopic liver transplantation

Mastroianni

Greco²,

Mauro³

et al. 2022

Medical Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…lobally, viral hepatitis accounts for a considerable burden of morbidity and mortality. Hepatitis B (HBV) and hepatitis C (HCV) are the most common causes of chronic liver disease in different regions 1 and the majority of cirrhosis and hepatocellular carcinoma has been attributed to either virus. 2 In 2002, 103,000 and 53,000 deaths worldwide were estimated to be directly caused by HBV and HCV, respectively.…”

mentioning

confidence: 99%

“…5 Among HCV-infected persons, 60-85% will develop chronic HCV infection. 6 Because HBV and HCV share common risk factors and routes of transmission, 1,7 co-infection is not uncommon. 8 Co-infection with two or more hepatitis viruses is associated with poorer outcomes and accelerated progression of liver disease.…”

mentioning

confidence: 99%

“…8 Co-infection with two or more hepatitis viruses is associated with poorer outcomes and accelerated progression of liver disease. 1,[7][8][9] Although the burden of illness associated with HBV/HCV coinfection is substantial, few studies have detailed its epidemiology and none have described it in the general Canadian population. This study identifies chronic HBV/HCV co-infection among all HBV and HCV reported cases in British Columbia (BC) since 1991, probably the largest cohort from North America.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Identification of Chronic Hepatitis B and Hepatitis C Co-infection in British Columbia from 1991 to 2007

Fang

Buxton

2009

Can J Public Health

View full text Add to dashboard Cite

Objectives: To determine the chronic HBV/HCV co-infection identification rate in British Columbia, and examine the demographic characteristics, the order of virus identification, and trends of co-infection over time. Methods: All newly identified cases of chronic HBV/HCV co-infection between 1991 and October 2007 were extracted from the BC integrated Public Health Information System. Differences according to sex and order of hepatitis identification were evaluated using chi-square, t-tests, and ANOVA. Results: Of 1,815 HBV/HCV co-infected residents, 71.6% were male and the mean age at co-infection diagnosis was 40.5 years (95% CI, 40.0-41.0; range 3-85 years). Among all persons identified with HCV infection, 3.1% were identified as co-infected with HBV and 5.2% of all chronic HBV-infected were diagnosed with HCV. Annual co-infection identification rates peaked at 5.3 per 100,000 in 1996. Females were significantly younger when they were first diagnosed with a hepatitis virus (p=0.0005) at 35.2 years (95% CI, 34.0-36.5; range 3-79 years) than males at 37.9 years (95% CI, 37.0-39.7; range 4-85 years). The majority of co-infections consisted of concurrent diagnoses until 2003; since then, the number of co-infected cases identified with HBV first, HCV first and concurrent virus identification is similar. Discussion: HBV/HCV co-infection identification rates have declined since the late 1990s, but appropriate testing and identification for both viruses are important. Some co-infection cases may be prevented through HBV vaccination and harm reduction activities for those with or at risk for HCV.

show abstract

Clinical Features and Outcome of Chronic Viral Hepatitis with Acute Exacerbation in Patients with Concurrent Infections of Hepatitis B and C Virus

Cited by 6 publications

References 19 publications

Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis

Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis

Fulminant hepatitis by concurrent acute HBV-HCV infection successfully treated with antivirals while seeking for an orthotopic liver transplantation

Identification of Chronic Hepatitis B and Hepatitis C Co-infection in British Columbia from 1991 to 2007

Contact Info

Product

Resources

About